No Data
No Data
Is Replimune Group (NASDAQ:REPL) A Risky Investment?
Leerink Partners Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $21
Analysts Offer Insights on Healthcare Companies: Waters (WAT), Alkermes (ALKS) and Replimune Group (REPL)
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $27
Jefferies Maintains Replimune(REPL.US) With Buy Rating, Raises Target Price to $31
HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $22